Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6598 Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05594043Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of MK-6598 in solid tumor (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 24 months and 1 more. Started Dec 2022; status: completed.
02
Drugs
MK-6598
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05594043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594043.